Impact Factor
3.16
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.65
248 total citations
h5-index
24
h5 depth signal
Cited share
64.9%
61 of 94
Total citations
248
Citation footprint
Metric signal
3.02
External metric anchor
Self-citation
8.5%
21 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
207
United Kingdom
74
Australia
43
Canada
40
Netherlands
34
Citing Fields of Research
Neurodegenerative Disorders
416
Cell Biology
17
Neurosciences
15
DNA Damage
9
Chronobiology
8
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
617
Articles tracked across the journal lifetime
Indexed publication set
94
61 cited publications
Last 12 months
59
4.9 publications/month
Open access share
32.2%
19 OA publications in the last year
Leading citing country
United States
207 citing publications
Leading citing field
Neurodegenerative Disorders
416 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 2012-
v1n1, 2012-
Research Focus & Classification
Indexed Subjects
Neurodegenerative Disorders
Broad Categories
Neurology
Neurodegenerative Disorders
MeSH Descriptors
Huntington Disease
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/18796397261459542
Open DOI
Autonomic dysfunction in patients with Huntington's disease: Evidence from standardized cardiovascular reflex testing
Background: Autonomic dysfunction has been reported in Huntington's disease (HD), but its extent and mechanisms remain unclear. This study aimed to evaluate autonomic function using standardized cardiovascular autonomic reflex tests (CRT...
02
DOI 10.1177/18796397261499360
Open DOI
Huntington's disease clinical trials update: August 2026
In this edition, we highlight several important developments across the Huntington's disease therapeutic pipeline. We discuss the launch and subsequent discontinuation of POINT-HD, the first-in-human phase I study of RG6496 (Hoffmann-La ...
03
DOI 10.1177/18796397261497434
Open DOI
iPSC neurodegenerative disease initiative isogenic CAG repeat iPSC line for Huntington's disease
Purpose of Research: The generation of iPSC lines expressing 21, 56 and 79 glutamine repeats within the HTT protein and homozygous KO of HTT in the KOLF2.1J background as an additional disease series within the iPSC Neurodegenerative Dis...
04
DOI 10.1177/18796397261494078
Open DOI
Directing mutant huntingtin towards degradation: Strategies and therapeutic opportunities
Huntington's Disease (HD) is a progressive neurodegenerative disease that is caused by a CAG-repeat expansion in the exon 1 of the huntingtin ( HTT ) gene, which results in the formation of toxic mutant HTT (mHTT) exon 1 fragments with e...
05
DOI 10.1177/18796397261490952
Open DOI
Defective membrane dynamics in Huntington's disease: A role of Rab11 dysfunction
Huntington's disease (HD) is a life-threatening neurodegenerative disease caused by a mutation in Huntingtin (HTT). Neuropathology in HD is marked by a progressive loss of neurons in the caudate putamen and the deposition of mutant HTT a...
06
DOI 10.1177/18796397261489245
Open DOI
Esketamine for treatment of depression in Huntington's disease: A case report
Depression and suicidal ideation are common in Huntington's disease (HD). We report a 60-year-old male with HD who suffered from treatment-resistant depression with intermittent suicidal thoughts for 20 years, irritability and apathy. De...
07
DOI 10.1177/18796397261478173
Open DOI
Chaperone-assisted selective autophagy (CASA) in polyglutamine-related diseases: From mechanisms to therapeutic perspectives
Chaperone-assisted selective autophagy (CASA) is a crucial process aimed at maintaining proteostasis in several neurodegenerative diseases associated with protein misfolding, including polyglutamine (polyQ) diseases. Autophagy is a criti...
08
DOI 10.1177/18796397261480227
Open DOI
Huntingtin, signaling endosomes and neuronal survival in health and Huntington disease
The axonal transport of organelles mediates several functions throughout the lifespan of neurons. Over the past years, the role of endosomes, a specific type of trafficking organelle, has been extensively investigated for their increasin...
09
DOI 10.1177/18796397261478175
Open DOI
Indicators of need and timing of percutaneous endoscopic gastrostomy (PEG) in people with Huntington's disease: A medical chart review study
Background: In the International guidelines for nutrition in Huntington's disease (HD) PEG-tubes may be considered in persons with HD (pwHD) with severe swallowing difficulties, but there are no general recommendations for when to initia...
10
DOI 10.1177/18796397261468393
Open DOI
Multimodal balance training with rhythmical auditory cueing in Huntington's disease: A pilot randomized controlled trial
Background: Balance impairments in Huntington's Disease (HD) are common but difficult to treat. Objectives: We aimed to investigate the potential effects and feasibility of multimodal physiotherapy balance intervention in HD. Method: In ...
Bibliographical & Catalog Notes
Also issued online.